Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Phase 2 Trial of Oral S-1 Combined with Low-dose Cisplatin for Unresectable Advanced Pancreatic Cancer

SHINOMI INA, MASAJI TANI, MANABU KAWAI, SEIKO HIRONO, MOTOKI MIYAZAWA, RYOHEI NISHIOKA, YOICHI FUJITA and HIROKI YAMAUE
Anticancer Research July 2008, 28 (4C) 2373-2377;
SHINOMI INA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAJI TANI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MANABU KAWAI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SEIKO HIRONO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MOTOKI MIYAZAWA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RYOHEI NISHIOKA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOICHI FUJITA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROKI YAMAUE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: yamaue-h@wakayama-med.ac.jp
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Objectives: A phase 2 trial of S-1 combined with cisplatin was conducted for unresectable pancreatic cancer. Patients and Methods: S-1 was administered for 28 days followed by a rest of 14 days. Cisplatin was infused on days 1-5, 8-12, 15-19 and 22-26 of the first course. After the second course, S-1 was administered as maintenance chemotherapy. Results: Thirty patients were enrolled and the responses observed were 0 complete response, 5 partial response, 22 stable disease and 3 progressive disease, with an overall response rate of 17% (95% confidence internal (CI), 6-35%). Toxicity was tolerable, with grade 3 toxicities observed for leukocytopenia (10%), neutropenia (7%), anemia (3%), thrombocytopenia (3%), anorexia (13%), and nausea and vomiting (7%). The median survival time (MST) and the 1-year survival rate were 9.0 months (95% CI, 6.0-14.5 months) and 35.7% (95% CI, 19-55%), respectively. Conclusion: S-1 with low-dose cisplatin is well tolerated and effective for advanced pancreatic cancer.

  • S-1
  • cisplatin
  • advanced pancreatic cancer
  • phase II study

Footnotes

  • Received February 4, 2008.
  • Revision received May 2, 2008.
  • Accepted May 6, 2008.
  • Copyright© 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 28 (4C)
Anticancer Research
Vol. 28, Issue 4C
July-August 2008
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Phase 2 Trial of Oral S-1 Combined with Low-dose Cisplatin for Unresectable Advanced Pancreatic Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
13 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Phase 2 Trial of Oral S-1 Combined with Low-dose Cisplatin for Unresectable Advanced Pancreatic Cancer
SHINOMI INA, MASAJI TANI, MANABU KAWAI, SEIKO HIRONO, MOTOKI MIYAZAWA, RYOHEI NISHIOKA, YOICHI FUJITA, HIROKI YAMAUE
Anticancer Research Jul 2008, 28 (4C) 2373-2377;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Phase 2 Trial of Oral S-1 Combined with Low-dose Cisplatin for Unresectable Advanced Pancreatic Cancer
SHINOMI INA, MASAJI TANI, MANABU KAWAI, SEIKO HIRONO, MOTOKI MIYAZAWA, RYOHEI NISHIOKA, YOICHI FUJITA, HIROKI YAMAUE
Anticancer Research Jul 2008, 28 (4C) 2373-2377;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Radiomics for Growth Prediction of Vestibular Schwannomas in Neurofibromatosis Type 2
  • Chemotherapy-induced Moderate to Severe Peripheral Neuropathy in Patients Receiving Adjuvant Radiotherapy for Breast Cancer
  • Efficacy and Prognostic Factors of Surgical Resection for Pulmonary Metastases From Ovarian Cancer
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire